OPT 0.90% 56.0¢ opthea limited

Ann: Opthea to Host Key Opinion Leader Event on April 3, 2024, page-29

  1. 111 Posts.
    lightbulb Created with Sketch. 102
    Hi FreeFromStyle,

    I would rather expect Opthea‘s two P3 trials to be reported as a single make-or-break announcement as you say.

    Reason being the real world experience with the two most recent wAMD drugs:

    Vabysmo (farizimab, ROG):
    LUCERNE reported primary completion date Oct 5, 2020
    TENAYA reported primary completion date Oct 26, 2020
    Both reported topline data the same day on Jan 25, 2021, that‘s three months post TENAYA‘s PCD.

    Beovu (brolucizumab, NOVN):
    HARRIER reported primary completion date Apr 5, 2017
    HAWK reported primary completion date Apr 22, 2017
    Both reported topline data the same day on Jun 20, 2017, that‘s two months post HAWK‘s PCD.

    So, assuming ShORe announcing full enrollment later in April and primary completion date being 52 weeks later, we could assume topline data for both COAST and ShORe to be reported simultaneously in the June/July 2025 time frame.
 
watchlist Created with Sketch. Add OPT (ASX) to my watchlist
(20min delay)
Last
56.0¢
Change
0.005(0.90%)
Mkt cap ! $689.4M
Open High Low Value Volume
55.0¢ 56.5¢ 55.0¢ $1.173M 2.097M

Buyers (Bids)

No. Vol. Price($)
2 30360 55.5¢
 

Sellers (Offers)

Price($) Vol. No.
57.0¢ 35361 3
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
OPT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.